HEADACHE CLINICAL TRIALS

TEVA48125-CNS-300049:  A multicenter, randomized, Double Blind, placebo controlled,  parallel-group study comparing the efficacy and safety of 2 dose regiments of subcutaneous administration of TEVA-48125 versus placebo for the preventive treatment of chronic migraine.

Sponsor: Teva Pharmaceutical Industries

Phase of Development: Phase III

Study Duration: 16 weeks

 Enrollment Status: Closed                                                                          

TEVA48125-CNS-300050:  A multicenter, randomized, Double Blind, placebo controlled,  parallel-group study comparing the efficacy and safety of 2 dose regiments of subcutaneous administration of TEVA-48125 versus placebo for the preventive treatment of episodic migraine.

Sponsor: Teva Pharmaceutical Industries

Phase of Development: Phase III

Study Duration: 16 weeks

Enrollment Status: Closed

TEVA48125-CNS-30051:  A multicenter, randomized, double-blind, parallel-group study evaluating the long term safety, tolerability and efficacy of subcutaneous administration of TEVA-48125 for the preventive treatment of migraine.

Sponsor: Teva Pharmaceutical Industries

Phase of Development: Phase III

Study Duration: This is an 18 month rollover study from TEVA48125-CNS-300049 and TEVA48125-CNS-300050 

Enrollment Status: Closed

UBR-MD-02:  A multicenter, randomized, double blind, placebo controlled, single attack study to evaluate the efficacy, safety and tolerability of oral Ubrogepant in the acute treatment of migraine.

Sponsor: Allergan

Phase of Development: Phase III

Study Duration: Up to 14 days for the screening period prior to randomization, a 60-day period which to treat a single migraine attack, and a 4-week follow up period. (This study can last 1.5-4 months based on the treatment of a single migraine attack).

Enrollment Status: Open

UBR-MD-04:  A multicenter, randomized, open-label extension study to evaluate the long-term safety and tolerability of oral Ubrogepant in the acute treatment of migraine with or without aura.

Sponsor: Allergan

Phase of Development: Phase III

Study Duration: This is a 52 week rollover study from UBR-MD-01 and UBR-MD-02

Enrollment Status: Closed

Principal Investigator for the above clinical trials: Jessica Heiring, MD

Research Contacts:
Tracy Anderson, RN SC 763-302-4099
Katelynn Rehs, SC 763-302-4035